The group reviews data from ASCO 2019 that evaluated novel agents for EGFR-positive non–small cell lung cancer; of particular interest is targeting EGFR exon 20 insertions.
Novel EGFR Exon 20 Directed Therapies for NSCLC
The group reviews data from ASCO 2019 that evaluated novel agents for EGFR-positive non–small cell lung cancer; of particular interest is targeting EGFR exon 20 insertions.
0 Comments